Bulletin
Investor Alert

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Regeneron Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 24, 2023, 7:48 p.m.

REGN
/zigman2/quotes/203149337/composite

$

822.00

Change

+2.00 +0.24%

Volume

Volume 21,657

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Previous close

$ 802.16

$ 820.00

Change

+17.84 +2.22%

Day low

Day high

$801.01

$824.00

Open

52 week low

52 week high

$538.01

$824.00

Open

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accel...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Valuation

P/E Current

20.99

P/E Ratio (with extraordinary items)

21.08

P/E Ratio (without extraordinary items)

18.88

Price to Sales Ratio

6.73

Price to Book Ratio

3.49

Price to Cash Flow Ratio

16.33

Enterprise Value to EBITDA

14.94

Enterprise Value to Sales

6.79

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

1,027,162.00

Income Per Employee

366,079.00

Receivables Turnover

2.14

Total Asset Turnover

0.45

Liquidity

Current Ratio

5.06

Quick Ratio

4.29

Cash Ratio

2.46

Profitability

Gross Margin

84.38

Operating Margin

42.63

Pretax Margin

39.91

Net Margin

35.64

Return on Assets

15.86

Return on Equity

20.94

Return on Total Capital

22.16

Return on Invested Capital

18.82

Capital Structure

Total Debt to Total Equity

11.92

Total Debt to Total Capital

10.65

Total Debt to Total Assets

9.23

Long-Term Debt to Equity

11.92

Long-Term Debt to Total Capital

10.65

Officers and Executives

Name Age Officer Since Title
Dr. P. Roy Vagelos 90 1995 Chairman
Dr. Leonard S. Schleifer 68 1988 Co-President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos 59 1989 Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly - 1998 Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry 57 2013 Chief Financial Officer & Executive VP-Finance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/22/2023 P. Roy Vagelos
Director 		29,005   Derivative/Non-derivative trans. at $750.16 per share. 21,758,390
02/22/2023 P. Roy Vagelos
Director 		42,500   Derivative/Non-derivative trans. at $270.43 per share. 11,493,275
02/12/2023 Marion McCourt
EVP Commercial 		1,276   Derivative/Non-derivative trans. at $751.78 per share. 959,271
02/07/2023 Marion McCourt
EVP Commercial 		1,000   Disposition at $769.04 per share. 769,040
02/07/2023 Marion McCourt
EVP Commercial 		1,000   Derivative/Non-derivative trans. at $372.46 per share. 372,460
02/06/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		13,189   Disposition at $800.08 per share. 10,552,255
02/06/2023 Robert E. Landry
EVP Finance CFO 		28   Disposition at $797.43 per share. 22,328
02/06/2023 Robert E. Landry
EVP Finance CFO 		18   Disposition at $796.43 per share. 14,335
02/06/2023 Robert E. Landry
EVP Finance CFO 		59   Disposition at $795.41 per share. 46,929
02/06/2023 Robert E. Landry
EVP Finance CFO 		99   Disposition at $794.61 per share. 78,666
02/06/2023 Robert E. Landry
EVP Finance CFO 		2   Disposition at $793.33 per share. 1,586
02/06/2023 Robert E. Landry
EVP Finance CFO 		3   Disposition at $791 per share. 2,373
02/06/2023 Robert E. Landry
EVP Finance CFO 		10   Disposition at $790.41 per share. 7,904
02/06/2023 Robert E. Landry
EVP Finance CFO 		49   Disposition at $789.05 per share. 38,663
02/06/2023 Robert E. Landry
EVP Finance CFO 		99   Disposition at $788.62 per share. 78,073
02/06/2023 Robert E. Landry
EVP Finance CFO 		58   Disposition at $787.47 per share. 45,673
02/06/2023 Robert E. Landry
EVP Finance CFO 		85   Disposition at $786.45 per share. 66,848
02/06/2023 Robert E. Landry
EVP Finance CFO 		78   Disposition at $785.88 per share. 61,298
02/06/2023 Robert E. Landry
EVP Finance CFO 		113   Disposition at $784.27 per share. 88,622
02/06/2023 Robert E. Landry
EVP Finance CFO 		51   Disposition at $783.05 per share. 39,935
02/06/2023 Michael S. Brown
Director 		500   Disposition at $797 per share. 398,500
02/06/2023 Michael S. Brown
Director 		3,071   Disposition at $798 per share. 2,450,658
02/06/2023 Joseph L. Goldstein
Director 		3,613   Disposition at $800 per share. 2,890,400
02/06/2023 Michael S. Brown
Director 		3,071   Derivative/Non-derivative trans. at $520.01 per share. 1,596,950
02/06/2023 Joseph L. Goldstein
Director 		3,613   Derivative/Non-derivative trans. at $482.68 per share. 1,743,922
02/03/2023 Robert E. Landry
EVP Finance CFO 		2,248   Derivative/Non-derivative trans. at $774.29 per share. 1,740,603
02/03/2023 Christopher Robert Fenimore
SVP Controller 		3,286   Derivative/Non-derivative trans. at $774.29 per share. 2,544,316
02/03/2023 Robert E. Landry
EVP Finance CFO 		739   Disposition at $764.5 per share. 564,965
02/03/2023 Bonnie L. Bassler
Director 		1,021   Disposition at $779 per share. 795,359
02/03/2023 Robert E. Landry
EVP Finance CFO 		3,000   Derivative/Non-derivative trans. at $381.92 per share. 1,145,760
02/03/2023 Christopher Robert Fenimore
SVP Controller 		5,000   Derivative/Non-derivative trans. at $270.43 per share. 1,352,150
02/03/2023 Bonnie L. Bassler
Director 		1,021   Derivative/Non-derivative trans. at $380.95 per share. 388,949
02/01/2023 Marion McCourt
EVP Commercial 		1,100   Disposition at $752.19 per share. 827,409
02/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $762.17 per share. 1,524
02/01/2023 Arthur Frederick Ryan
Director 		3   Disposition at $761.58 per share. 2,284
02/01/2023 Arthur Frederick Ryan
Director 		4   Disposition at $760.4 per share. 3,041
02/01/2023 Arthur Frederick Ryan
Director 		4   Disposition at $759.65 per share. 3,038
02/01/2023 Arthur Frederick Ryan
Director 		7   Disposition at $758.58 per share. 5,310
02/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $757.29 per share. 1,514
02/01/2023 Arthur Frederick Ryan
Director 		24   Disposition at $756.77 per share. 18,162
02/01/2023 Arthur Frederick Ryan
Director 		17   Disposition at $755.5 per share. 12,843
02/01/2023 Arthur Frederick Ryan
Director 		17   Disposition at $754.45 per share. 12,825
02/01/2023 Arthur Frederick Ryan
Director 		18   Disposition at $753.54 per share. 13,563
02/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $752.11 per share. 1,504
02/01/2023 Marion McCourt
EVP Commercial 		1,100   Derivative/Non-derivative trans. at $372.46 per share. 409,706
01/27/2023 Michael S. Brown
Director 		1   Disposition at $747 per share. 747
01/27/2023 Michael S. Brown
Director 		1   Derivative/Non-derivative trans. at $520.01 per share. 520
01/06/2023 Michael S. Brown
Director 		3,070   Disposition at $747.14 per share. 2,293,719
01/06/2023 Michael S. Brown
Director 		3,070   Derivative/Non-derivative trans. at $520.01 per share. 1,596,430
01/04/2023 P. Roy Vagelos
Director 		291   Gift at $0 per share. 0
01/03/2023 George L. Sing
Director 		165   Award at $0 per share. 0
01/03/2023 Arthur Frederick Ryan
Director 		165   Award at $0 per share. 0
01/03/2023 Michael S. Brown
Director 		165   Award at $0 per share. 0
01/03/2023 Joseph L. Goldstein
Director 		165   Award at $0 per share. 0
01/03/2023 Marc Tessier-Lavigne
Director 		165   Award at $0 per share. 0
01/03/2023 Marc Tessier-Lavigne
Director 		165   Award at $0 per share. 0
01/03/2023 Christine A. Poon
Director 		165   Award at $0 per share. 0
01/03/2023 N. Anthony Coles
Director 		165   Award at $0 per share. 0
01/03/2023 Huda Y. Zoghbi
Director 		165   Award at $0 per share. 0
01/03/2023 Bonnie L. Bassler
Director 		165   Award at $0 per share. 0
01/03/2023 Craig B. Thompson
Director 		40   Award at $0 per share. 0
01/03/2023 Marion McCourt
EVP Commercial 		1,100   Derivative/Non-derivative trans. at $372.46 per share. 409,706
01/03/2023 Marion McCourt
EVP Commercial 		1,100   Disposition at $721.86 per share. 794,046
01/03/2023 Arthur Frederick Ryan
Director 		2   Disposition at $732.18 per share. 1,464
01/03/2023 Arthur Frederick Ryan
Director 		12   Disposition at $731.59 per share. 8,779
01/03/2023 Arthur Frederick Ryan
Director 		4   Disposition at $730.35 per share. 2,921
01/03/2023 Arthur Frederick Ryan
Director 		1   Disposition at $729.92 per share. 729
01/03/2023 Arthur Frederick Ryan
Director 		11   Disposition at $728.34 per share. 8,011
01/03/2023 Arthur Frederick Ryan
Director 		13   Disposition at $727.59 per share. 9,458
01/03/2023 Arthur Frederick Ryan
Director 		10   Disposition at $726.34 per share. 7,263
01/03/2023 Arthur Frederick Ryan
Director 		9   Disposition at $725.63 per share. 6,530
01/03/2023 Arthur Frederick Ryan
Director 		9   Disposition at $724.52 per share. 6,520
01/03/2023 Arthur Frederick Ryan
Director 		10   Disposition at $723.52 per share. 7,235
01/03/2023 Arthur Frederick Ryan
Director 		5   Disposition at $722.59 per share. 3,612
01/03/2023 Arthur Frederick Ryan
Director 		14   Disposition at $721.48 per share. 10,100
/news/latest/company/us/regn

MarketWatch News on REGN

  3. Regeneron upgraded to market perform from underperform at Raymond James

    6:18 a.m. March 24, 2023

    - Tomi Kilgore

  6. Regeneron, Sanofi say Dupixent works in COPD

    7:56 a.m. March 23, 2023

    - Jaimy Lee

  8. Biosimilar Pricing Looks a Mess. Why Costly Drugs Prevail.

    6:48 p.m. Feb. 21, 2023

    - Josh Nathan-Kazis

  9. 9 Healthcare Stocks Where the Doubters Are on the Run

    9:00 a.m. Feb. 15, 2023

    - Josh Nathan-Kazis

  12. Regeneron Q4 revenue falls 31% to $3.41 bln but beats the FactSet consensus $3.13 bln; stock gains 1.9% premarket

    6:33 a.m. Feb. 3, 2023

    - Tomi Kilgore

  13. Regeneron Q4 adj. EPS $12.56 falls from $23.42 a year ago, but beats the FactSet consensus $10.17

    6:32 a.m. Feb. 3, 2023

    - Tomi Kilgore

  14. Apple, Amazon, Fed Decision, Jobs, and More

    8:43 a.m. Jan. 30, 2023

    - Nicholas Jasinski

  15. Stocks Poised for Muted Open

    6:26 p.m. Jan. 29, 2023

    - Janet H. Cho

  16. Gasoline Prices Are Rising. A Major Beneficiary: Refiners.

    11:04 a.m. Jan. 28, 2023

    - Avi Salzman

  19. Regeneron Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan

    7:07 a.m. Jan. 20, 2023

    - Tomi Kilgore

  20. Covid Isn't Going Away. New Drugs Are Coming.

    9:00 a.m. Jan. 18, 2023

    - Josh Nathan-Kazis

  21. Loading more headlines...
/news/nonmarketwatch/company/us/regn

Other News on REGN

  1. Regeneron, Sanofi Look for Billions From COPD Drug

    12:54 p.m. Today

    - The Wall Street Journal Interactive Edition

  2. Regeneron Borrows From Big Pharma Playbook

    2:33 a.m. March 13, 2023

    - The Wall Street Journal Interactive Edition

  3. LOOMIS SAYLES & CO L P Buys 2, Sells 3 in 4th Quarter

    9:00 a.m. Feb. 12, 2023

    - GuruFocus.com

  5. Freedom Day Solutions, LLC Buys 3, Sells 2 in 4th Quarter

    11:00 a.m. Feb. 8, 2023

    - GuruFocus.com

  6. Top 5 4th Quarter Trades of MCDONALD CAPITAL INVESTORS INC/CA

    7:00 p.m. Feb. 7, 2023

    - GuruFocus.com

  7. Top 5 4th Quarter Trades of Pacer Advisors, Inc.

    7:00 p.m. Feb. 6, 2023

    - GuruFocus.com

  9. Top 5 4th Quarter Trades of Tom Gayner

    11:00 p.m. Feb. 3, 2023

    - GuruFocus.com

  10. SEIZERT CAPITAL PARTNERS, LLC Buys 3, Sells 2 in 4th Quarter

    7:00 p.m. Jan. 30, 2023

    - GuruFocus.com

  11. Covenant Asset Management, LLC Buys 3, Sells 2 in 4th Quarter

    7:00 p.m. Jan. 24, 2023

    - GuruFocus.com

  13. Old Port Advisors Buys 3, Sells 2 in 4th Quarter

    3:00 p.m. Jan. 11, 2023

    - GuruFocus.com

  14. Nasdaq Rises, as Dow and S&P 500 Slip

    4:12 a.m. Jan. 10, 2023

    - The Wall Street Journal Interactive Edition

  15. Where Are the Next Covid Treatments?

    4:30 p.m. Jan. 10, 2023

    - The Wall Street Journal Interactive Edition

  16. As the U.S. Gets Older, Some ETFs Bet on Aging in Place

    2:54 a.m. Jan. 16, 2023

    - The Wall Street Journal Interactive Edition

  19. FDA Pulls Lilly’s Covid Antibody Drug

    2:06 a.m. Dec. 1, 2022

    - The Wall Street Journal Interactive Edition

  20. A Post-Thanksgiving Feast of GARP Stocks

    10:42 a.m. Nov. 28, 2022

    - GuruFocus.com

  21. Loading more headlines...

At a Glance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Phone

1 9148477000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$12.17B

Net Income

$4.34B

Employees

11,851

Annual Report for REGN

/news/pressrelease/company/us/regn

Press Releases on REGN

  1. S&P 500 Movers: FDS, NFLX

    10:25 a.m. March 23, 2023

    - MarketNewsVideo.com

  2. Nasdaq 100 Movers: PYPL, NFLX

    10:21 a.m. March 23, 2023

    - MarketNewsVideo.com

  7. Regeneron Pharmaceuticals $REGN Proactive Strategies

    3:24 a.m. March 21, 2023

    - Stock Traders Daily

  12. Regeneron Pharmaceuticals $REGN Pivots Trading Plans and Risk Controls

    11:39 a.m. March 11, 2023

    - Stock Traders Daily

  13. Nasdaq 100 Movers: TEAM, VRTX

    11:45 a.m. March 10, 2023

    - MarketNewsVideo.com

  17. Regeneron Pharmaceuticals $REGN Investment Report

    8:49 p.m. March 1, 2023

    - Stock Traders Daily

  21. Loading more headlines...
Link to MarketWatch's Slice.